2024-13-005 + 2023-12-006 - X-Ra FINE-02 - X-Ra biomarker For agIng, caNcer and fErtility

We recently patented and published the discovery of X-Ra, a novel female-specific biomarker that assesses X-chromosome inactivation (XCI) using blood samples. X-Ra is a validated analytical tool that quantifies defective XCI through methylation data. Preliminary evidence indicates that X-Ra is a promising marker for reproductive potential, pregnancy outcomes, and fertility monitoring. It offers valuable insights to improve clinical decisions and personalize fertility treatments, marking a significant advancement in women's reproductive health.

2023-12-021 - IONET - Solid-State Ionics Synaptic Transistors for Neuromorphic Computing

A new generation of robust and reliable solid-oxide synaptic transistors to be applied in neuromorphic computing that provide the required stability, low-energy consumption and viable operating temperature

2023-12-015 + 2021-08-009 - ALL-BePrecise-2 - Precision medicine in infant t(4;11) pro-B-ALL: targeting the novel biomarker HDAC7

Acute lymphoblastic leukemia (ALL) derived from B cell progenitors (pro-B-ALL) is the most prevalent type of cancer among children that are annually diagnosed of leukemia in Western countries. Despite an 80% of pediatric B-ALL remission has been achieved, a specific subgroup of infant patients (<1 year old) that present a translocation between chromosomes 4 and 11, commonly relapse, converting acute leukemia into the main cause of pediatric cancer-associated death. Survival rate of infants diagnosed with t(4;11) pro-B-ALL does not even reach 35%. Due to their short age and vulnerability, these patients are normally excluded from clinical trials rendering them to no further opportunities than non-targeted chemotherapy or "off-label" use of available drugs. Therefore, there is an urgent need to improve current available therapies. Recently, Dr Maribel Parra's group has identified HDAC7 as a prognostic factor in infants with this aggressive leukemia. These patients display a general loss in HDAC7 expression. The lowest levels of HDAC7 are associated with a poor outcome of the patients. Additional results show that HDAC7 is also lost in adult patients with t(4;11) pro-B-ALL and diffuse large B cell lymphoma (DLBCL), both aggressive diseases with low survival. Therefore, the identification of those blood cancer patients with low HDAC7 levels is a promising approach to implement personalized medicine strategies aiming to specifically induce HDAC7 expression. In this sense, a novel combinatorial therapy is being developed comprising MI-538 and Chidamide with the capacity to trigger HDAC7 expression in t(4;11) pro-B-ALL cells.

2023-12-002 - MD-NAF - Massively Decentralized Network Automation Framework

The proposed Massively Decentralized (MD) Network Automation Framework (NAF) (MD-NAF) technology focuses on creating a new NAF where multiple network locations run a portion of that NAF. This NAF portion is not only responsible for the co-located equipment, but can also provide support for managing neighbour locations, for instance, in during peaks of infrastructure management workload, system upgrades, or even failures. The envisioned technology will enable infrastructure and network operators to provide high-quality services in 5G and beyond infrastructures while keeping the Total Cost of Ownership at reasonable levels.

2023-12-010 - VariantX_Patent - IP rights related to a novel gene-therapy based product as a key tool in the treatment of liver-related diseases

VariantX consists of a potential new gene therapy for the treatment of endoplasmic reticulum (ER)-stress-related liver disorders (ERSLD).

2023-12-005 - FIRSTGUT2 - NOVEL ENZYME THERAPY FOR INFLAMMATORY BOWEL DISEASE

The proposal, participating in GíNJOL call, we aim to get a FTO that will complement other development, market and patent-related activities already funded.

2023-12-013 - J4L - Join 4 Life

2023-12-017 - NICAH - Innovative multi-metallic NItrides as CAtalyst towards Hydrogen industrial production

The ICIQ proprietary technology describes a general methodology towards the access to metallic nitrides and an especific multimetallic nitride composition with outstanding properties as catalysts for the hydrogen production through AEM technology.

2023-12-020 - MbBOOST - Novel immunomodulator agent for improving immune health against infections

Multidrug-resistant bacteria (MDR) are strains of bacteria that have become resistant to multiple antibiotics, difficult or even impossible to treat with conventional antibiotics. Researchers at IBEC have developed an immunomodulator (MbBOOST) that offers a promising non-antibiotic alternative for the treatment of bacterial infections, especially those caused by MDR, as they have the potential to modulate the host's immune system to combat the pathogens. Our technology has demonstrated to drastically reduce or eliminate infections from resistant bacteria from our infection models. We plan to further validate the technology and maturate it into a product that can reduce the use of antibiotics and decrease the rate of antibiotic resistance globally.

2023-12-019 - BrainTAG - Delivering Therapies to the Brain by Generating Artificial Brain-Specific Targets

A new peptide-based delivery platform to direct therapy-loaded nanoparticles to the brain by generating 'artificial' targets selectively on the brain vasculature. The platform, termed Brain Targets Artificially Generated (Brain-TAG), differs form current delivery strategies employing 'natural' targets with inherent brain-spceficity and safety limitations. Therefore, Brain-TAG has the potential to achive truly brain-specific therapy delivery against a wide range of brain disorders.

2023-12-016 - Antimalarial YAT - Development of a new family of Irresistible Antimalarial drugs with a Novel mechanism of Action

Malaria is the first parasitic disease in number of deaths. The currently used drugs are becoming increasingly useless due to rapid evolution of resistance in the parasites. Based on our current results, we propose the development of a new drug with potent in vitro activity against Plasmodium. Our preliminary data indicate that this new compounds will be highly active and stable without the need for refrigeration, significantly impervious to resistance, with an optimal activity/toxicity ratio, of easy and rapid synthesis, and with a good cost/activity balance; all these characteristics are unavoidably expected within the current clinical and economic landscape of malaria.

2023-12-012 - NeuroSwitch - Light-Modulated Drugs to Restore Neuronal Activity in Neurological Disorders

Neurological drugs, electrical and magnetic stimulations of the nervous system are clinically used to treat tremor and Parkinson’s disease, Schizophrenia, Alzheimer’s, and provide important benefits to patients, their families, and society. However, possess very important drawbacks, from high toxicity to invasiveness and high costs. In our laboratory, we have developed a series of compounds based on photopharmacology principles, with the unique advantage of controlling the neuronal signalling using light. Our strategy would allow for a safe use of potent neurological drugs, non-invasively, with a high spatiotemporal resolution of activation.

2023-12-007 - CONAN (Controlled-replication ONcolytic AdeNovirus): Generation of a controlled-replication oncolytic adenovirus for cancer treatment